Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hyperkalemia: early-phase trial registry
3 of 9 indexed Hyperkalemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Hyperkalemia: 9 US clinical trials tracked, 3 recruiting.
Hyperkalemia is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Relypsa, running 1 of these trials.
Enrollment posture brief
Registry condition hyperkalemia
OPEN 3 | RECR 33% | LATE 2 | EARLY 5 | RANK #1916 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Hyperkalemia lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hyperkalemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hyperkalemia is recruiting below its size-band peers.
3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hyperkalemia trials is spread across many organizations.
Relypsa accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Hyperkalemia trials plan to enrol fewer than 100 people.
Median target enrolment is 36 among the 9 trials that report a genuine target (sentinel values excluded). 7 of those (77.8%) plan for fewer than 100 participants.
-
Hyperkalemia research is mostly interventional.
8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
AccurKardia
NCT07210021
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
Vifor Pharma
NCT05766839
Adding Urea to the Final Dialysis Fluid
University of California, San Francisco
NCT06366230
Evaluation of Patiromer in Heart Failure Patients
Relypsa
NCT00868439
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
Ardelyx
NCT04780841
Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia
ZS Pharma
NCT01493024
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
Duke University
NCT03781089
Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns
The University of Texas Health Science Center, Houston
NCT01349218
Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
The Rogosin Institute
NCT03229265
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Hyperkalemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hyperkalemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hyperkalemia page
9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Hyperkalemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Relypsa sponsors the most Hyperkalemia trials on record, review their full trial history before evaluating a specific study. See Relypsa's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hyperkalemia condition card totals 9 registered trials; most-linked intervention Patiromer; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.